Clinical data of DALD patients
Patient no. . | Sex . | Age, y* . | IgG, mg/dL† . | OPN, ng/mL† . | OPN genotype . | ANA . | AM . | HM . | SM . | Autoimmunities . |
---|---|---|---|---|---|---|---|---|---|---|
1 | M | 6 | 966 | 332 | AB | + | + | + | + | AHA, AN, T, RF |
2 | M | 10 | 1100 | 254 | AA | - | + | - | + | AN, E |
3 | M | 16 | 506 | ND | CC | - | + | - | + | AN, T |
4 | M | 9 | 1143 | 286 | AC | + | - | - | + | AHA, A |
5 | F | 18 | 2775 | 426 | AB | + | - | - | + | AN, RF |
6 | M | 16 | 2810 | 405 | CC | - | + | - | + | T, IH |
7 | F | 24 | 1259 | 337 | AC | + | - | + | + | AHA, IH |
8 | F | 15 | 1019 | 222 | AC | + | - | - | + | AHA, T, A1 |
9 | M | 16 | 1132 | 340 | AB | + | - | + | + | AHA, T, IH |
10 | M | 11 | 679 | 90 | AA | + | + | + | + | AHA, T, V |
11 | F | 11 | 1542 | 347 | AB | + | + | - | + | AHA, |
12 | F | 17 | 836 | 211 | AC | +/- | - | - | + | AHA, T, E |
13 | M | 15 | 1153 | 298 | AC | - | + | - | - | T |
14 | M | 5 | 900 | 156 | AC | + | + | - | + | T |
15 | M | 10 | 1117 | 226 | AC | + | + | + | + | AN, T, IH |
16 | M | 33 | 984 | 494 | BC | ND | + | + | + | AN, T, A1 |
17 | M | 6 | 878 | 109 | CC | + | + | - | - | T |
18 | F | 7 | 1180 | 167 | AA | + | + | + | + | AHA, AN, T, E, A, C, SR, RF |
19 | M | 10 | 830 | 103 | AC | + | + | - | + | IDDM, T, A1, AN |
20 | M | 6 | ND | 37 | AC | + | + | - | + | AN, T |
21 | M | 13 | ND | 383 | AC | - | + | - | + | AN |
22 | F | 3 | ND | 187 | AB | + | + | + | + | SR |
23 | M | 17 | 2110 | 356 | AC | + | + | + | + | AHA, AN, T, RF |
24 | F | 9 | 842 | 147 | AC | + | - | - | + | T |
25 | M | 2 | ND | 512 | AC | + | + | - | + | AHA, IH, T |
26 | M | 11 | ND | 365 | AB | ND | + | + | + | AN, T |
Patient no. . | Sex . | Age, y* . | IgG, mg/dL† . | OPN, ng/mL† . | OPN genotype . | ANA . | AM . | HM . | SM . | Autoimmunities . |
---|---|---|---|---|---|---|---|---|---|---|
1 | M | 6 | 966 | 332 | AB | + | + | + | + | AHA, AN, T, RF |
2 | M | 10 | 1100 | 254 | AA | - | + | - | + | AN, E |
3 | M | 16 | 506 | ND | CC | - | + | - | + | AN, T |
4 | M | 9 | 1143 | 286 | AC | + | - | - | + | AHA, A |
5 | F | 18 | 2775 | 426 | AB | + | - | - | + | AN, RF |
6 | M | 16 | 2810 | 405 | CC | - | + | - | + | T, IH |
7 | F | 24 | 1259 | 337 | AC | + | - | + | + | AHA, IH |
8 | F | 15 | 1019 | 222 | AC | + | - | - | + | AHA, T, A1 |
9 | M | 16 | 1132 | 340 | AB | + | - | + | + | AHA, T, IH |
10 | M | 11 | 679 | 90 | AA | + | + | + | + | AHA, T, V |
11 | F | 11 | 1542 | 347 | AB | + | + | - | + | AHA, |
12 | F | 17 | 836 | 211 | AC | +/- | - | - | + | AHA, T, E |
13 | M | 15 | 1153 | 298 | AC | - | + | - | - | T |
14 | M | 5 | 900 | 156 | AC | + | + | - | + | T |
15 | M | 10 | 1117 | 226 | AC | + | + | + | + | AN, T, IH |
16 | M | 33 | 984 | 494 | BC | ND | + | + | + | AN, T, A1 |
17 | M | 6 | 878 | 109 | CC | + | + | - | - | T |
18 | F | 7 | 1180 | 167 | AA | + | + | + | + | AHA, AN, T, E, A, C, SR, RF |
19 | M | 10 | 830 | 103 | AC | + | + | - | + | IDDM, T, A1, AN |
20 | M | 6 | ND | 37 | AC | + | + | - | + | AN, T |
21 | M | 13 | ND | 383 | AC | - | + | - | + | AN |
22 | F | 3 | ND | 187 | AB | + | + | + | + | SR |
23 | M | 17 | 2110 | 356 | AC | + | + | + | + | AHA, AN, T, RF |
24 | F | 9 | 842 | 147 | AC | + | - | - | + | T |
25 | M | 2 | ND | 512 | AC | + | + | - | + | AHA, IH, T |
26 | M | 11 | ND | 365 | AB | ND | + | + | + | AN, T |
ANA indicates antinuclear antibodies; AM, adenomegaly; HM, hepatomegaly; SM, splenomegaly; +, presence; -, absence; AHA, autoimmune hemolytic anemia; AN, autoimmune neutropenia; T, thrombocytopenia; RF, recurrent fever; E, eczema; ND, not determined; A, arthritis; IH, immune hepatitis; AI, alopecia; V, vitiligo; C, celiac disease; SR, skin rush; and IDDM, insulin-dependent diabetes mellitus.
Age at study.
Serum levels; 95th percentile of control OPN levels = 298 ng/mL.